Indi Molecular

📍 Culver City, United States🗓 Founded 2013👥 4 employees💰 Last funded Sep 2020
Biotechnology Research🌐 indimolecular.com
Website LinkedIn
Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
2
Frequently asked questions
Who invested in Indi Molecular?
Indi Molecular has 2 investors on record on gritt.io and 2 late-stage investors.
When did Indi Molecular last raise funding?
The most recent investment in Indi Molecular recorded on gritt.io was in September 2020.
When was Indi Molecular founded?
Indi Molecular was founded in 2013.
What industry is Indi Molecular in?
Indi Molecular operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Indi Molecular based?
Indi Molecular is headquartered in Culver City, United States.